DMRA
Damora Therapeutics, Inc.
Latest Form 4:Sale$7KbyWinslow Garrett (General Counsel) · filed Jul 8, 2026
Damora Therapeutics, Inc. (DMRA) has 2 SEC Form 4 filings (3 transaction rows) in the rolling window, disclosed by 1 distinct insider. Most recent filing: Jul 8, 2026.
- Industry:Biotechnology
- CEO:Jennifer A. Jarrett
- Employees:7
- HQ:Waltham, MA, US
- IPO:2026-03-10
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7K
reported sales (SEC code S)
Unique Insiders
1
in the rolling window
Market Cap
$1.9B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Winslow GarrettFirst in 6 months | General Counsel | Sale | 245 | $7K | Jul 8 | SEC ↗ |
Related companies
Damora Therapeutics, Inc. is in the Healthcare sector.